European and USA Pharmaceutical Directory 2015
![](/46/pdcnewsitem/03/42/43/FqVkf3iBc3Rxfob.jpg)
Research and Markets has announced the addition of the "European and USA Pharmaceutical Directory 2015" directory to their offering.
This new directory combines both the whole database of the European Pharmaceutical Directory and the USA Pharmaceutical Directory into one set of books and onto one set of CD-ROMs.
The European & USA Pharmaceutical Directory has been thoroughly researched, to provide a completely up-to-date guide to Europe's & America's ever-changing pharmaceutical industries.
If you sell or buy Pharmaceuticals, Biotechnology products, Biopharmaceuticals, Bulk Pharmaceuticals, OTC/Healthcare products, Fine Chemicals, Generics, Genomics, or Diagnostics/Reagents; or, if you're looking to break into this appealing market, the new European & USA Pharmaceutical Directory will provide you with thousands of fresh business contacts — and help you keep track of old ones — quickly and easily.
This new Directory covers the entire European & USA pharmaceutical & biotechnology industry sector, including
• Pharmaceuticals; Biotechnology; Biopharmaceuticals; Bulk Pharmaceuticals; Drug Delivery
• OTC/Healthcare Products; Clinical Research; Research & Development
• Ethical Pharmaceuticals; Fine Chemicals; Generics; Genomics; Contract Manufacturers
• Contract Research; Cosmetics; Diagnostics/Reagents; Licensing
• Plus 30 more categories
Listing more than 7500 companies, entries in The European & USA Pharmaceutical Directory feature
• Full company contact details, including telephone and fax
• Web and email addresses
• Names of key management and trading personnel
• Locations of offices
• Main product information
• Number of employees
This combined Directory will enable you to
• Profile a market
• Build new business prospects
• Pinpoint key executives
• Generate new customers
• Discover who your competitors are
• Make vital contacts
• Save the time, money and effort of doing your own research
• Identify alternative suppliers and manufacturers
• Source up-to-date company information
• Access a wealth of quality information on healthcare companies.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance